NCT05932589 Neurophysiologic Biomarkers in Rett Syndrome
| NCT ID | NCT05932589 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital of Philadelphia |
| Condition | Rett Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 202 participants |
| Start Date | 2023-10-11 |
| Primary Completion | 2028-03-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study is to identify candidate biomarkers in individuals with Rett Syndrome (RTT). The main questions it aims to answer are: * Do these biomarkers change during clinical changes in individuals with RTT? * Are biomarkers stable over time in clinically stable individuals? * Do these biomarkers correlate with severity of RTT? Participants will be asked to undergo an electroencephalogram (EEG) with measurements of Evoked Potentials (EP) to measure electrical activity in the brain. Researchers will compare findings in individuals with RTT to those in typically developing individuals to see if there are differences between the two groups.
Eligibility Criteria
Inclusion Criteria: 1. Rett Group: Females ages 3-18 (inclusive) with a clinical diagnosis of RTT with a likely pathogenic or known pathogenic variant in MECP2. 2. Likely Rett Group: Females from 1 year to \< 5 years of age with MECP2 variant if regression has not yet occurred or child is within 6 months of last skill loss. 3. Typically developing (TD) Group: Females age matched to RTT population (1-18) with no developmental or cognitive concerns as assessed using the Child/Adult Behavioral Checklist, Survey of Well-Being of Young Children (\<5yo), or the Wide Range Achievement Test-4 (\>5 yo). Exclusion Criteria: Rett and Likely Rett Groups: 1. Presence of a duplication in MECP2 or any other identified pathogenic mutation in another gene. 2. Active medical conditions not typically found in RTT. Typically Developing Group: 1. Score below norms on the performance tests 2. Have a known neurological disorder (excluding migraine) 3. Being on neuroactive medications.